Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheeba K Thomas

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
Annals of Hematology|June 28, 2019
Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemiaNeeraj Y Saini, Romil D Patel, Ankur Varma, et al.
American Journal of Hematology|January 11, 2012
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myelomaQaiser Bashir, Hassan Khan, Robert Z Orlowski, et al.
British Journal of Haematology|March 14, 2023
Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplantOren Pasvolsky, Rima M Saliba, Adeel Masood, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 2, 2019
Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell TransplantationDavid M Cordas Dos Santos, Rima M Saliba, Romil Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 29, 2019
Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?Adnan Elhammali, Sarah A Milgrom, Behrang Amini, et al.
Transplantation and Cellular Therapy|August 8, 2022
Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple MyelomaOren Pasvolsky, Denái R Milton, Mikael Rauf, et al.
Transplantation and Cellular Therapy|October 24, 2024
Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17pCurtis Marcoux, Oren Pasvolsky, Denái R Milton, et al.
Transplantation and Cellular Therapy|September 6, 2023
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple MyelomaOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Cancer|December 21, 2023
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantationOren Pasvolsky, Sarah Pasyar, Roland L Bassett, et al.
American Journal of Hematology|July 18, 2023
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experienceOren Pasvolsky, Denái R Milton, Adeel Masood, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
Annals of Hematology|June 28, 2019
Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemiaNeeraj Y Saini, Romil D Patel, Ankur Varma, et al.
American Journal of Hematology|January 11, 2012
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myelomaQaiser Bashir, Hassan Khan, Robert Z Orlowski, et al.
British Journal of Haematology|March 14, 2023
Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplantOren Pasvolsky, Rima M Saliba, Adeel Masood, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 2, 2019
Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell TransplantationDavid M Cordas Dos Santos, Rima M Saliba, Romil Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 29, 2019
Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?Adnan Elhammali, Sarah A Milgrom, Behrang Amini, et al.
Transplantation and Cellular Therapy|August 8, 2022
Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple MyelomaOren Pasvolsky, Denái R Milton, Mikael Rauf, et al.
Transplantation and Cellular Therapy|October 24, 2024
Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17pCurtis Marcoux, Oren Pasvolsky, Denái R Milton, et al.
Transplantation and Cellular Therapy|September 6, 2023
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple MyelomaOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Cancer|December 21, 2023
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantationOren Pasvolsky, Sarah Pasyar, Roland L Bassett, et al.
American Journal of Hematology|July 18, 2023
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experienceOren Pasvolsky, Denái R Milton, Adeel Masood, et al.
Pageof 12